Get started
ABBVIE INCABBVIE INCABBVIE INC

ABBVIE INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

ABBV trade ideas

Leaning Bullish on ABBV after Strong Reaction to EarningsABBV had a solid reaction to earnings. The tight consolidation over the last few days supports a bullish momentum holding up. Volume declining over the last few days (when price has been declining) typically means a healthy consolidation before a continued rise. While the price may/may not continue down a bit more, if it starts to climb back up, the 201 area would be a place I'd consider an entry (either call option or stock). I'd place a stop around 194, and a first profit target when the price extends again from its 10EMA. That area of 201 for entry will be where the price rises above the moving averages on the 15m and 1h chart time frames, and the 10EMA crossing back above the 20EMA on the 15m timeframe. 1h
NYSE:ABBVLong
by emanuelaelias
3
ABBVIE broke below the 1D MA50. Confirmed sell opportunity.AbbVie Inc. (ABBV) has been trading within a Channel Up pattern since the November 09 2023 Low. Having made a Higher High on September 04 and been rejected at the top of the Channel Up, the price broke and closed aggressively below its 1D MA50 (blue trend-line) three days ago. That is a confirmed technical sell signal. The 1D RSI has been on Lower Highs before the actual High, very similar to the previous top on March 12 2024. That sequence, after breaking below its 1D MA50, extended aggressively towards the 1D MA200 (orange trend-line) and bottomed on the 0.618 Fibonacci retracement level. As a result, we can take a low risk sell now and target a potential contact with the 1D MA200 at $180.00. As far as buying the dip for the long-term is concerned, the most consistent buy signal has been the 1D RSI Bullish Divergence when it forms the first Higher Lows sequence after breaking below the 30.00 oversold barrier. So far that has worked 3 times almost perfectly, with the only exception the May 29 2024 bottom, which still was formed not that far away from the April 26 buy signal. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:ABBVShort
by TradingShot
2
ABBV ZonesAll rectangles are potential zones of influence for support/resistance pressure. Same applies to the 2 curves. 1st, I don't know if the red will prove to offer more resistance to the price as initially suspected, or failing and triggering a penetration. 2nd, even if it does prove to be a resistance force zone, don't know if the price will manage to squeeze between it and the purple I am a little bearish biased for now as the project also suggests with the descending rectangles, but will be following the price action especially near any of the elements in the design, to watch out for any rebounds from these shapes. If the situation changes I might add other rectangles especially on the upside which is not covered, in case the earnings push this in bullish territory, but we might not need them.
NYSE:ABBV
by nen
ABBV Comprehensive analysisChart Analysis: 1. Asset: AbbVie Inc. (ABBV) on NYSE 2. Timeframe: 1-hour chart 3. Date Range: August 2023 to September 2024 (future projection) Price Action and Trend Analysis: The chart shows a bullish trend from August 2023 to June 2024, with the price rising from around $150 to a peak of about $170. There are several notable features: 1. Strong upward momentum from November 2023 to January 2024. 2. Consolidation phase from January to May 2024. 3. Recent breakout to new highs in June 2024. Support and Resistance Levels: - Major support: $155.12 - Minor support: $163.60 - Current resistance/sell point: $170.83 - Previous resistance turned support: $165.21 Volume Analysis: Without clear volume bars, it's challenging to make a definitive volume-based analysis. However, the presence of multiple long and short positions indicated on the chart suggests active trading periods. Technical Indicators: RSI-VWAP Indicator (17, 19, 80) is visible at the bottom of the chart, currently reading 57.20. This indicates: 1. The asset is not overbought or oversold (neutral territory). 2. There's still potential for upward movement before reaching overbought conditions. Trading Strategy and Projections: The chart includes a projected trading strategy with the following key points: 1. Current price: $170.83 2. Sell Point identified at the current price level 3. Projected price movement: A decline followed by a period of consolidation 4. Take Profits level: Around $155.12 Risk and Reward Scenario: - Potential Reward: If the projected decline occurs, there's a potential for a 9.2% return from the current price to the Take Profits level. - Risk: The asset is at all-time highs, which could lead to continued bullish momentum, invalidating the short-term bearish projection. Trading Opportunities: 1. Short-term Short Position: - Entry: Current price ($170.83) - Stop Loss: Above recent high (e.g., $172.00) - Take Profit: $155.12 - Risk-Reward Ratio: Approximately 1:3 2. Long-term Long Position: - Entry: At support level ($163.60 or $155.12) - Stop Loss: Below the entered support level - Take Profit: New all-time highs above $171.00 Anomalies and Divergences: The rapid price increase from May to June 2024 without a clear consolidation phase might indicate potential overextension of the bullish trend. Conclusion: ABBV shows a strong overall uptrend but appears to be at a critical juncture. The chart suggests a potential short-term bearish move, followed by consolidation. However, traders should be cautious of the overall bullish trend and the possibility of continued upward movement. Risk Management: Always use proper position sizing and stop-loss orders. The volatile nature of this asset, as evidenced by large price swings, necessitates strict risk management. Note: This analysis is based solely on the technical aspects visible in the provided chart. Fundamental analysis and broader market conditions should also be considered before making any trading decisions.
NYSE:ABBVShort
by Trustscore
ABBV - Increase in Probability of ValuationAlignment and compression of fibo clouds within the 15min to Daily spectrum signal an entry of direction and strength towards the first target. Proper management with partial achievement of the first target could authorize the search for the second target with reduced risk in the operation. Follow us if you want to receive new analyses and updates on this and other markets, including cryptocurrencies in different time frames. You can check out other recent studies by clicking on our profile. Have a good week!
NYSE:ABBVLong
by EthosInvest
AbbVie Faces Humira Headwinds: Stock Dips 4.76%AbbVie Inc. ( NYSE:ABBV ) struggles with declining sales volumes of its blockbuster arthritis drug, Humira. Despite a positive outlook for its newer immunology treatments, Skyrizi and Rinvoq, concerns over the impact of biosimilar competition and shifting patient preferences have cast a shadow over the pharmaceutical giant's performance, leading to a dip in its stock price. Humira Volume Erosion Worries Weigh on AbbVie AbbVie's forecast of a 32% decline in U.S. Humira sales for the second quarter has sent ripples through the market, with investors expressing apprehension over the escalating erosion of the drug's market share. The introduction of biosimilars and changes by U.S. pharmacy benefit managers have contributed to the anticipated decline, prompting AbbVie ( NYSE:ABBV ) to brace for a challenging road ahead. Navigating the Biosimilar Landscape Despite the onslaught of biosimilar competition, AbbVie ( NYSE:ABBV ) remains steadfast in its efforts to retain market dominance, emphasizing its ability to retain the majority of the Humira market. However, concerns linger as health insurer Cigna's plans to offer biosimilar alternatives without out-of-pocket payments threaten to further impact Humira's volume, adding to the company's woes. Focus on Skyrizi and Rinvoq In light of the Humira sales decline, AbbVie ( NYSE:ABBV ) has intensified its focus on promoting its newer immunology treatments, Skyrizi and Rinvoq, as key drivers of future growth. The company's raised annual profit forecast reflects confidence in the performance of these drugs, which have demonstrated strong sales in the first quarter, surpassing analyst expectations. Strategic Adjustments Amidst Uncertainty AbbVie's proactive measures to address the challenges posed by Humira's erosion underscore its commitment to resilience and adaptability in the face of market headwinds. With a revised profit forecast and robust sales performance of Skyrizi and Rinvoq, AbbVie remains poised to weather the storm and emerge stronger, reaffirming its position as a leading player in the pharmaceutical industry. Conclusion: AbbVie's outlook amidst the backdrop of Humira volume erosion reflects the dynamic nature of the pharmaceutical landscape, where innovation and adaptability are essential for long-term success. As the company continues to navigate through challenges posed by biosimilar competition and shifting market dynamics, its strategic focus on newer treatments and proactive measures will be critical in shaping its trajectory in the months ahead.
NYSE:ABBVShort
by DEXWireNews
AbbVie Poised to Expand in Neurobiology with Cerevel AcquisitionPharmaceutical giant AbbVie Inc. is considering enhancing its neurobiological portfolio as it finalises the acquisition of neurobiotech firm Cerevel Therapeutics. Initially announced in December 2023 for 8.7 billion USD, the acquisition was primarily focused on Cerevel's experimental schizophrenia drug, Emraclidine. This drug represents a new class of psychiatric medications that have recently sparked increased interest within the pharmaceutical industry. The deal's prospects have been further boosted by promising clinical trial results from Cerevel's Parkinson's disease drug, reinforcing the strategic fit of this acquisition for AbbVie. The company's broad portfolio diversification, consistent dividend payments, and stable positive cash flow make AbbVie's securities attractive to investors. Examining the technical analysis of AbbVie Inc. (NYSE: ABBV) for potential investment opportunities: On the Daily (D1) timeframe, the stock has formed a support level at 161.50 USD and resistance at 170.55 USD. The stock is currently in a downtrend within a channel and is nearing the upper boundary of this trend. A breakout above the downtrend line could lead to a break of the resistance and initiate an uptrend. Conversely, if the stock breaks below the support level, the next target could be 151.50 USD. For traders, purchasing the stock if it breaks the resistance at 170.55 USD could make sense, with a short-term price target set at 182.10 USD. For those looking at a medium-term investment, holding a long position with a target of up to 195.00 USD can be considered. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:ABBV
by RoboMarkets
ABBV - cautious with this dipNYSE:ABBV is a great company. It's part of my long-term portfolio and is one that I've been able to manage well with technical analysis. I am not adding unless I see price fall to 155 or until we get to August/September where it hits its seasonal low. This drawdown has risk of continuation for a number of reasons: Momentum was falling as price was rising. Drawdowns after this type of divergence usually have more challenging recoveries. The candle body on 4/4 is the spread in price to go against the long term uptrend. These are strong warnings of a reversal. It lost the YTD AVWAP and is struggling to hold the VWAP anchored to the November low. If this area fails we'll see investors begin to sell to protect profit. There is a large airgap down to 155., which is the lowest that price can fall while remaining in a primary uptrend. A fibonacci time zone drawn at momentum crossovers in April 2023 and June 2023 gives a view of an overall price cycle. The next time zone is August 2024, which aligns to a season
NYSE:ABBV
by Ben_1148x2
☀️ABBV BUY☀️Entry Price (173.97) : Chosen based on Fibonacci retracement levels, suggesting a potential point to buy or enter the stock, expecting the price to increase from this level. Take Profit (179.97) : Set near a Fibonacci extension or resistance level, indicating a target price to sell and secure profits before the stock might pull back. Stop Loss (171.97) : Established to limit potential losses, placed below a key Fibonacci or support level, indicating where to exit the trade if the price unexpectedly drops. Current Price (178.88) : The stock is presently above the entry point but hasn't reached the profit target, suggesting the possibility of a minor pullback before moving higher towards the target. This strategy uses Fibonacci levels to identify strategic entry, exit, and profit-taking points, reflecting anticipated price movements based on historical patterns and market psychology. ☀️ABBV BUY☀️ 💲Entry Price : 173.97 💰TP1 : 179.97 🏳️SL : 171.97
NYSE:ABBVLong
by mildDiamond6018